Researchers studied a diabetes medication called semaglutide to see if it could help protect people’s hearts. Nearly 10,000 people with type 2 diabetes and heart disease took either the medication or a placebo for about 4 years. The results showed that people taking semaglutide had better numbers for blood sugar control, weight loss, blood pressure, and cholesterol levels compared to those taking placebo. These improvements started quickly and lasted throughout the entire study, suggesting this medication may help reduce heart disease risk in people with diabetes.
The Quick Take
- What they studied: Whether a daily pill called oral semaglutide could improve heart disease risk factors in people with type 2 diabetes who already have heart disease or kidney problems
- Who participated: 9,495 adults with an average age of 66 years who had type 2 diabetes and either existing heart disease or chronic kidney disease. About 29% were women. All participants were already receiving standard diabetes and heart care.
- Key finding: People taking semaglutide showed better improvements in blood sugar control, weight loss, blood pressure, and cholesterol levels compared to those taking placebo. These benefits appeared within 13 weeks and stayed consistent for the entire 3+ year study period.
- What it means for you: If you have type 2 diabetes with heart disease or kidney problems, this medication may help reduce your heart disease risk by improving multiple health markers. However, this was a study of people with serious health conditions, so talk to your doctor about whether it’s right for you.
The Research Details
This was a large, double-blind randomized controlled trial, which is considered one of the strongest types of medical research. Double-blind means neither the participants nor the researchers knew who was getting the real medication versus the placebo (fake pill), which helps prevent bias. Participants were randomly assigned to receive either oral semaglutide (a pill taken once daily) or placebo, and everyone continued their regular diabetes and heart medications.
The study enrolled people between June 2019 and March 2021, and followed them for an average of about 47 months (nearly 4 years). Researchers measured multiple health markers at the beginning, at 13 weeks, and throughout the study to track changes over time. The measurements included blood sugar control (HbA1c), body weight, blood pressure, inflammation markers, and cholesterol levels.
This research design is important because it shows cause-and-effect relationships rather than just associations. By randomly assigning people to groups and using placebos, researchers could be confident that improvements were due to the medication itself, not other factors. The long follow-up period (nearly 4 years) is also crucial because it shows whether benefits last over time, which matters for real-world treatment decisions.
This study has several strengths: it’s large (nearly 10,000 participants), has a very high completion rate (98.4% of people finished), used a rigorous double-blind design, and lasted nearly 4 years. The study was published in a top medical journal (JAMA Cardiology). However, participants were mostly older (average age 66) and only 29% were women, so results may not apply equally to younger people or all demographic groups. The study focused on people with serious health conditions, so findings may not apply to people with milder diabetes.
What the Results Show
The medication showed benefits across multiple heart disease risk factors. For blood sugar control, people taking semaglutide had their HbA1c (a measure of average blood sugar over 3 months) drop by 0.47 percentage points more than placebo by the end of the study. Body weight decreased by about 3.26% more in the semaglutide group. Blood pressure (specifically systolic pressure, the top number) dropped about 1.83 mm Hg more with the medication.
Cholesterol and inflammation markers also improved. Total cholesterol decreased by about 7%, and triglycerides (another type of blood fat) dropped by about 8% in the semaglutide group compared to placebo. A marker of inflammation in the blood (hsCRP) decreased by about 18% early in the study and remained lower throughout. Good cholesterol (HDL-C) actually increased slightly more in the semaglutide group.
Importantly, these improvements appeared quickly—within just 13 weeks—and were sustained throughout the entire study period. This means the benefits didn’t fade over time, which is important for long-term disease prevention.
The study found that pulse pressure (the difference between top and bottom blood pressure numbers) improved by about 2.17 mm Hg more with semaglutide. This is significant because pulse pressure is an independent risk factor for heart disease. However, the medication did not significantly improve LDL cholesterol (the ‘bad’ cholesterol) or diastolic blood pressure (the bottom number), suggesting the benefits were selective for certain risk factors.
Previous research showed that semaglutide reduced major heart disease events by 14% in this same group of patients. This new analysis helps explain how the medication works by showing it improves multiple underlying risk factors that contribute to heart disease. The findings align with other research on similar medications in this class, though the sustained benefits over nearly 4 years add important new information about long-term effectiveness.
This study focused on people with serious health conditions (existing heart disease or kidney disease), so results may not apply to people with milder diabetes. The group was relatively old (average age 66) and mostly male (71%), so benefits might differ for younger people or women. The study was conducted in controlled research settings with careful monitoring, which may not reflect real-world conditions where people might miss doses or have less oversight. Additionally, the study didn’t measure whether these risk factor improvements actually translated to fewer heart attacks or strokes in this particular analysis, though the main trial showed a 14% reduction in major heart events.
The Bottom Line
For people with type 2 diabetes who have heart disease or chronic kidney disease, oral semaglutide appears to be a beneficial addition to standard care (moderate to high confidence based on this large, well-designed study). The medication should be considered as part of a comprehensive treatment plan that includes diet, exercise, and other medications. People without existing heart disease or kidney disease should not assume these results apply to them without consulting their doctor.
This research is most relevant for people with type 2 diabetes who already have heart disease or chronic kidney disease. Their doctors may want to discuss whether semaglutide is appropriate for them. People with type 2 diabetes but without heart disease or kidney problems should not assume they need this medication based on this study. People with type 1 diabetes or those without diabetes should not consider this medication based on this research.
Benefits appeared quickly, with meaningful improvements in blood sugar and weight within 13 weeks. However, the full cardiovascular benefits likely take longer to develop. Based on this study, you should expect to see sustained improvements over months and years of treatment, not just weeks. The actual reduction in heart disease risk would likely take even longer to become apparent.
Want to Apply This Research?
- Track weekly weight and daily blood sugar readings (if you test at home). Record these in your app along with medication adherence to see if you’re achieving similar improvements to the study participants. Also note any changes in energy levels or how you feel.
- If prescribed this medication, use your app to set reminders for taking your daily pill at the same time each day. Log your meals to understand how the medication affects your appetite and food choices. Many people on this medication experience reduced hunger, so tracking food intake helps you ensure you’re still getting adequate nutrition.
- Work with your healthcare provider to monitor key metrics every 3 months: HbA1c (blood sugar control), weight, and blood pressure. Use your app to track these results over time and share them with your doctor. Watch for patterns in how the medication affects your weight and energy levels. If you notice side effects or if improvements plateau, discuss adjustments with your healthcare team.
This research describes findings from a clinical trial in people with type 2 diabetes who have existing heart disease or kidney disease. These results may not apply to everyone with diabetes. Semaglutide is a prescription medication that requires medical supervision and is not appropriate for all people. Do not start, stop, or change any diabetes or heart medications without consulting your healthcare provider. This summary is for educational purposes and should not replace professional medical advice. Always discuss any new treatment options with your doctor to determine if they’re appropriate for your individual health situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.